Hormone receptor status in primary breast cancer - Time for a consensus?

European Journal of Cancer

Volumn 38, Issue 9, 2002, Pages 1201-1203

  Wishart, G C ^a   Gaston, M ^a   Poultsidis, A A ^a   Purushotham, A D ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Adjuvant therapy; Breast cancer; Oestrogen receptors; Progesterone receptors

Indexed keywords

ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; HUMAN; PRIORITY JOURNAL; QUESTIONNAIRE; STAINING; UNITED KINGDOM;

ATTITUDE OF HEALTH PERSONNEL; BREAST NEOPLASMS; DECISION MAKING; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM PROTEINS; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 0036275219     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00304-5     Document Type: Article

References (6)

1. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
2. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer
3. The importance, availability and measurement of oestrogen receptor status in the management of breast cancer in the United Kingdom- results of a nationwide survey
4. Oestrogen receptor status - No longer an optional extra
5. Immunohistochemical detection of steroid receptors in breast cancer: A working protocol
6. Oestrogen receptors and breast cancer